120 related articles for article (PubMed ID: 37425717)
1. TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver.
Reyes-Soffer G; Liu J; Thomas T; Matveyenko A; Seid H; Ramakrishnan R; Holleran S; Zaghloul N; Sztalryd-Woodle C; Pollin T; Ginsberg HN
medRxiv; 2023 Jun; ():. PubMed ID: 37425717
[TBL] [Abstract][Full Text] [Related]
2. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.
Liu J; Ginsberg HN; Reyes-Soffer G
Curr Opin Lipidol; 2024 Jun; 35(3):157-161. PubMed ID: 38465912
[TBL] [Abstract][Full Text] [Related]
3. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
[TBL] [Abstract][Full Text] [Related]
5. Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats.
Luo F; Smagris E; Martin SA; Vale G; McDonald JG; Fletcher JA; Burgess SC; Hobbs HH; Cohen JC
Cell Mol Gastroenterol Hepatol; 2022; 13(3):879-899. PubMed ID: 34923175
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
7. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
8. [Construction of transmembrane 6 superfamily member 2 E167K gene knock-in mouse model by using CRISPR/Cas9 technology].
Sun BK; Liu SS; Zhang J; Xuan SY; Xin YN
Zhonghua Gan Zang Bing Za Zhi; 2020 Jul; 28(7):591-596. PubMed ID: 32791795
[No Abstract] [Full Text] [Related]
9. The Genetics of Clinical Liver Diseases: Insight into the
Zhang X; Liu S; Dong Q; Xin Y; Xuan S
J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
[TBL] [Abstract][Full Text] [Related]
10. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
[TBL] [Abstract][Full Text] [Related]
12. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.
Mahdessian H; Taxiarchis A; Popov S; Silveira A; Franco-Cereceda A; Hamsten A; Eriksson P; van't Hooft F
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8913-8. PubMed ID: 24927523
[TBL] [Abstract][Full Text] [Related]
13. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
15. Human Induced Pluripotent Stem Cell based Hepatic-Modeling of Lipid metabolism associated TM6SF2 E167K variant.
Faccioli LA; Sun Y; Motomura T; Liu Z; Kurihara T; Hu Z; Cetin Z; Franks J; Stolz D; Ostrowska A; Florentino RM; Fox IJ; Soto-Gutierrez A
bioRxiv; 2023 Dec; ():. PubMed ID: 38187603
[TBL] [Abstract][Full Text] [Related]
16. TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6.
Du S; Liao S; Liu S; Xin Y
J Clin Transl Hepatol; 2019 Mar; 7(1):27-31. PubMed ID: 30944816
[No Abstract] [Full Text] [Related]
17. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
18. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
[TBL] [Abstract][Full Text] [Related]
19. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
[TBL] [Abstract][Full Text] [Related]
20. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
